<![CDATA[Genmab — Marts 2026]]>Wells Fargo initiated coverage of Genmab with an Overweight rating and $40 price target. The firm believes the company's upcoming Epkinly and petosemtamab readouts are "largely de-risked" based on the Ph2 data. In addition, Genmab shares at current levels do not reflect petosemtamab's potential beyond head and neck cancer, sees 2026 as 'inflection year' with multiple catalysts.

]]>https://dev.proinvestor.com/forum/topic/399206/genmab-marts-2026RSS for NodeSun, 07 Jun 2026 01:01:45 GMTMon, 02 Mar 2026 12:54:11 GMT60<![CDATA[Reply to Genmab — Marts 2026 on Tue, 31 Mar 2026 10:06:49 GMT]]>cool, thx for clarification

]]>https://dev.proinvestor.com/forum/post/7686762https://dev.proinvestor.com/forum/post/7686762Tue, 31 Mar 2026 10:06:49 GMT<![CDATA[Reply to Genmab — Marts 2026 on Tue, 31 Mar 2026 05:02:02 GMT]]>@concillado ; the rule is to inform of major shareholders holding >=5% . Orbis WAS above 5% but fell below that treshold this week, so that had to be reported. You will only hear about them again if they go above 5% again.

]]>https://dev.proinvestor.com/forum/post/7686767https://dev.proinvestor.com/forum/post/7686767Tue, 31 Mar 2026 05:02:02 GMT<![CDATA[Reply to Genmab — Marts 2026 on Tue, 31 Mar 2026 04:54:15 GMT]]>Viridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing https://www.fiercebiotech.com/biotech/viridians-other-rival-amgens-tepezza-scores-phase-3-win-investors-need-convincing Viridian fell >30% yesterday on this read out...

]]>https://dev.proinvestor.com/forum/post/7686760https://dev.proinvestor.com/forum/post/7686760Tue, 31 Mar 2026 04:54:15 GMT<![CDATA[Reply to Genmab — Marts 2026 on Tue, 31 Mar 2026 04:43:18 GMT]]>Så må vi se hvor lang tid Orbis har tænkt sig at blive i aktien. Får vi egentlig også besked, når/hvis
de mindsker deres beholdning?

]]>https://dev.proinvestor.com/forum/post/7686761https://dev.proinvestor.com/forum/post/7686761Tue, 31 Mar 2026 04:43:18 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 14:43:51 GMT]]>Orbis Investment Management Limited, på 4.99%

]]>https://dev.proinvestor.com/forum/post/7686763https://dev.proinvestor.com/forum/post/7686763Mon, 30 Mar 2026 14:43:51 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 10:04:12 GMT]]>@StockBull: Mange tak igen for dit tekniske perspektiv, det er værdsat herfra 🙂

]]>https://dev.proinvestor.com/forum/post/7686766https://dev.proinvestor.com/forum/post/7686766Mon, 30 Mar 2026 10:04:12 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 07:18:25 GMT]]>Vigtige forbehold
Dette er udelukkende tekniske estimater baseret på historisk pris- og RSI-adfærd fra grafen. Det er ikke en fundamental analyse og udgør ingen garanti for fremtidig udvikling. En enkelt større nyhed kan flytte kursen 10 % eller mere på få dage. Kombiner altid teknisk analyse med selskabsspecifikke nyheder og bredere markedsforhold.

]]>https://dev.proinvestor.com/forum/post/7686764https://dev.proinvestor.com/forum/post/7686764Mon, 30 Mar 2026 07:18:25 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 07:16:08 GMT]]>Baggrund for estimaterne
Genmab har historisk vist 15–30 % stigninger på 4–8 uger i mange rebound-perioder fra oversolgte RSI-niveauer – især i perioden 2015–2022. I de senere år (2022–2026) har reboundene været lidt mere afdæmpede, hvorfor estimaterne er holdt konservative. Aktien volatilitet understøtter dog fortsat potentielle bevægelser på 20–35 % over 6 uger, hvis der opstår positiv katalysator i form af pipeline-nyheder, regnskab eller bredere sektormomentum.

]]>https://dev.proinvestor.com/forum/post/7686758https://dev.proinvestor.com/forum/post/7686758Mon, 30 Mar 2026 07:16:08 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 07:14:55 GMT]]>I disse tilfælde toppede RSI typisk mellem 50 og 62, eller det tog længere tid end 60 dage at bryde niveauet.

Scenarier for medio maj 2026 (efter ca. 6 uger) Svagt rebound: Kursen lander i intervallet 1.820 – 1.900 DKK (RSI topper omkring 50–55).
Normalt rebound (mest sandsynlige scenarie): Kursen når 1.980 – 2.100 DKK (RSI i 60–65-området).
Stærkt rebound: Kursen stiger til 2.200 – 2.450 DKK (RSI over 70).

]]>https://dev.proinvestor.com/forum/post/7686765https://dev.proinvestor.com/forum/post/7686765Mon, 30 Mar 2026 07:14:55 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 30 Mar 2026 07:14:35 GMT]]>Aktuel situation (pr. 30. marts 2026)
Genmab-aktien handles i øjeblikket omkring 1.700 DKK. RSI(14) er steget moderat siden den 23. marts, hvor den lå på ca. 30,5, og befinder sig nu i området omkring 40–42.Historisk statistik (2010–marts 2026)
Over de seneste ca. 15 år har RSI(14) været under 30,5 i 18 klare episoder. Af disse tilfælde: 12 gange (67 %) nåede RSI over 65 inden for maksimalt 2 måneder (60 handelsdage).
6 gange (33 %) nåede RSI ikke over 65 inden for denne periode.

]]>https://dev.proinvestor.com/forum/post/7686756https://dev.proinvestor.com/forum/post/7686756Mon, 30 Mar 2026 07:14:35 GMT<![CDATA[Reply to Genmab — Marts 2026 on Sun, 29 Mar 2026 06:09:32 GMT]]>Yes - as Jan have said many times. Darzalex is a once in a lifetime drug. Lets hope one of the three late stage programs develops into something like that (just for Genmab).

]]>https://dev.proinvestor.com/forum/post/7686754https://dev.proinvestor.com/forum/post/7686754Sun, 29 Mar 2026 06:09:32 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 13:07:59 GMT]]>'From a development perspective, the partnership between Janssen Biotech and Genmab A/S to commercialize this therapy has resulted in its use by over 748,000 patients globally' https://www.pharmtech.com/view/implications-of-eu-approval-for-j-j-s-self-administered-daratumumab

]]>https://dev.proinvestor.com/forum/post/7686755https://dev.proinvestor.com/forum/post/7686755Fri, 27 Mar 2026 13:07:59 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 12:21:35 GMT]]>people would pop champagne here just a few years ago on such darzalex news ; today nobody gives a sh** lol

]]>https://dev.proinvestor.com/forum/post/7686759https://dev.proinvestor.com/forum/post/7686759Fri, 27 Mar 2026 12:21:35 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 12:11:49 GMT]]>Xian Deng

UBS
Buy Kr.2,600.00 Reiterated 26/3 2026

]]>https://dev.proinvestor.com/forum/post/7686752https://dev.proinvestor.com/forum/post/7686752Fri, 27 Mar 2026 12:11:49 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 12:04:33 GMT]]>Spændende udvikling https://finance.yahoo.com/sectors/healthcare/articles/johnson-johnson-darzalex-daratumumab-becomes-103100883.html

]]>https://dev.proinvestor.com/forum/post/7686749https://dev.proinvestor.com/forum/post/7686749Fri, 27 Mar 2026 12:04:33 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 08:14:28 GMT]]>Truist upgraded Genmab to “strong-buy” this week, from its prior Buy stance, according to a March 26 report (Truist had already had Genmab at Buy with a $48 target)

]]>https://dev.proinvestor.com/forum/post/7686753https://dev.proinvestor.com/forum/post/7686753Fri, 27 Mar 2026 08:14:28 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 06:10:20 GMT]]>MW" Genmab (+1,3%, 1693,50) har fået indledt dækning med anbefalingen "outperform" og kursmålet 32 dollar af børshuset Wolfe Research. Der går ti amerikanske ADR-aktier på én aktie i København, og dermed svarer kursmålet til 320 dollar - eller omregnet 2075 kr. "

]]>https://dev.proinvestor.com/forum/post/7686746https://dev.proinvestor.com/forum/post/7686746Fri, 27 Mar 2026 06:10:20 GMT<![CDATA[Reply to Genmab — Marts 2026 on Fri, 27 Mar 2026 05:08:16 GMT]]>Next…. 2027: Breakimg: Genmab fusionerer med Novo 😉

]]>https://dev.proinvestor.com/forum/post/7686751https://dev.proinvestor.com/forum/post/7686751Fri, 27 Mar 2026 05:08:16 GMT<![CDATA[Reply to Genmab — Marts 2026 on Thu, 26 Mar 2026 17:49:04 GMT]]>Ikke den store overraskelse. Next stop bestyrelsesformand.

]]>https://dev.proinvestor.com/forum/post/7686757https://dev.proinvestor.com/forum/post/7686757Thu, 26 Mar 2026 17:49:04 GMT<![CDATA[Reply to Genmab — Marts 2026 on Thu, 26 Mar 2026 15:40:41 GMT]]>Jan van de Winkel valgt som bestyrelsesmedlem i Novo!

]]>https://dev.proinvestor.com/forum/post/7686748https://dev.proinvestor.com/forum/post/7686748Thu, 26 Mar 2026 15:40:41 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 23 Mar 2026 07:49:51 GMT]]>RSI dagkort tæt på de 27 - købt flere i 1592 - GAK under 1800

]]>https://dev.proinvestor.com/forum/post/7686745https://dev.proinvestor.com/forum/post/7686745Mon, 23 Mar 2026 07:49:51 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 23 Mar 2026 07:00:42 GMT]]>Så er vi nede i 1500-regi

]]>https://dev.proinvestor.com/forum/post/7686747https://dev.proinvestor.com/forum/post/7686747Mon, 23 Mar 2026 07:00:42 GMT<![CDATA[Reply to Genmab — Marts 2026 on Mon, 23 Mar 2026 05:12:21 GMT]]>Genmabs anbefaling sættes op til "køb" hos Baptista https://proinvestor.com/investornyt/1424224/genmabs-anbefaling-saettes-op-til-kob-hos-baptista

]]>https://dev.proinvestor.com/forum/post/7686750https://dev.proinvestor.com/forum/post/7686750Mon, 23 Mar 2026 05:12:21 GMT<![CDATA[Reply to Genmab — Marts 2026 on Sat, 21 Mar 2026 07:20:27 GMT]]>also - Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study

]]>https://dev.proinvestor.com/forum/post/7686743https://dev.proinvestor.com/forum/post/7686743Sat, 21 Mar 2026 07:20:27 GMT